Title
Category
Credits
Event date
Cost
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Even with the advent of newer therapies in patients with T2D and CKD, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, residual morbidity, and mortality remain, and additional strategies to slow kidney disease progression, particularly to address inflammation and fibrosis as a contributing factor to CKD progression, are needed.
  • CMHC
  • 1.50 AAFP
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
$0.00
This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, and emerging insulin options. The information is presented in an interactive format, which contains a mix of high-impact visuals, infographics, expert faculty videos, as well as resources and suggested readings, all organized into different segments to facilitate learning.

Pages